(Q33330520)

25 July 2017

1 reference

title

A risk-benefit assessment of amifostine in cytoprotection (English)

1 reference

25 July 2017

S Faivre

2

0 references

author name string

M Mabro

series ordinal

1

1 reference

PubMed ID

10554052

25 July 2017

E Raymond

series ordinal

3

1 reference

25 July 2017

1 November 1999

1 reference

25 July 2017

1 reference

25 July 2017

21

1 reference

25 July 2017

5

1 reference

25 July 2017

367-387

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199921050-00003

25 July 2017

0 references

cites work

Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party

1 reference

12 December 2020

Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice

1 reference

12 December 2020

Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide

1 reference

12 December 2020

Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants

1 reference

12 December 2020

Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721

1 reference

12 December 2020

Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug

1 reference

12 December 2020

Human pharmacokinetics of WR-2721

1 reference

12 December 2020

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

12 December 2020

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

12 December 2020

Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.

1 reference

12 December 2020

Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors

1 reference

12 December 2020

Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro

1 reference

12 December 2020

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis

1 reference

12 December 2020

Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine.

1 reference

12 December 2020

Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

1 reference

12 December 2020

Differential chemoprotection of normal and malignant tissues

1 reference

12 December 2020

Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging

1 reference

12 December 2020

Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas

1 reference

12 December 2020

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1 reference

12 December 2020

Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721

1 reference

12 December 2020

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

12 December 2020

The long-term effect of cisplatin on renal function

1 reference

12 December 2020

Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721

1 reference

12 December 2020

Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.

1 reference

12 December 2020

Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neurons and 60Co gamma-rays in mice

1 reference

12 December 2020

Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma

1 reference

12 December 2020

Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse

1 reference

12 December 2020

Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.

1 reference

12 December 2020

Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide

1 reference

12 December 2020

Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid

1 reference

12 December 2020

Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial

1 reference

12 December 2020

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice

1 reference

12 December 2020

Use of radiation with or without WR-2721 in advanced rectal cancer

1 reference

12 December 2020

Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action

1 reference

12 December 2020

Radiochemotherapy with amifostine cytoprotection for head and neck cancer

1 reference

12 December 2020

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial

1 reference

12 December 2020

Autologous stem cell transplants in lymphomas.

1 reference

12 December 2020

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

1 reference

12 December 2020

Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support

1 reference

12 December 2020

Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors

1 reference

12 December 2020

Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients

1 reference

12 December 2020

Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival

1 reference

12 December 2020

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

1 reference

12 December 2020

Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man

1 reference

12 December 2020

Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721

1 reference

12 December 2020

Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained

1 reference

12 December 2020

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer

1 reference

12 December 2020

Distribution of 35 S-Labeled WR-2721 in Normal and Malignant Tissues of the Mouse

1 reference

12 December 2020

Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate

1 reference

12 December 2020

Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine

1 reference

12 December 2020

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

1 reference

12 December 2020

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

1 reference

12 December 2020

Antimutagenic effects of amifostine: clinical implications

1 reference

12 December 2020

The role of WR-2721 in radiotherapy and/or chemotherapy

1 reference

12 December 2020

WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

1 reference

12 December 2020

Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction

1 reference

12 December 2020

Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]

1 reference

12 December 2020

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma

1 reference

12 December 2020

10.2165/00002018-199921050-00003

Identifiers

DOI

1 reference

PubMed ID

10554052

Dimensions Publication ID

25 July 2017

0 references

1 reference

PubMed ID

10554052